Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1401-1410

  Zaineddin, Aida Karina ^a   Vrieling, Alina ^a   Buck, Katharina ^a   Becker, Susen ^a   Linseisen, Jakob ^b   Flesch Janys, Dieter ^c   Kaaks, Rudolf ^a   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

breast cancer; enterolactone; lignans; postmenopausal women

Indexed keywords

ENTEROLACTONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROGESTERONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER RISK; CELL HETEROGENEITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEEDING BEHAVIOR; FEMALE; HEALTH STATUS; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

4-BUTYROLACTONE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGENS; HUMANS; LIGNANS; LOGISTIC MODELS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84856087861     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26157     Document Type: Article

References (45)

1. Horn-Ross PL, Hoggatt KJ, West DW, Krone MR, Stewart SL, Anton H, Bernstei CL, Deapen D, Peel D, Pinder R, Reynolds P, Ross RK, et al. Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control 2002; 13: 407-15. (Pubitemid 34666596)
2. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM,. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 2003; 95: 1158-64. (Pubitemid 37045394)
3. Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H,. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Cancer Epidemiol Biomarkers Prev 2001; 10: 339-44. (Pubitemid 32703218)
4. Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J,. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 2006; 136: 1596-603. (Pubitemid 43765368)
5. Lacey M, Bohday J, Fonseka SM, Ullah AI, Whitehead SA,. Dose-response effects of phytoestrogens on the activity and expression of 3β- hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells. J Steroid Biochem Mol Biol 2005; 96: 279-86. (Pubitemid 41080509)
6. Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T, Arosemena PJ, Kellis JT Jr, Vickery LE,. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993; 44: 147-53. (Pubitemid 23072266)
7. Mense SM, Hei TK, Ganju RK, Bhat HK,. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Perspect 2008; 116: 426-33. (Pubitemid 351864298)
8. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE,. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat 2003; 77: 171-83.
9. Ganry O,. Phytoestrogen and breast cancer prevention. Eur J Cancer Prev 2002; 11: 519-22. (Pubitemid 35430654)
10. Adlercreutz H, Mazur W,. Phyto-oestrogens and Western diseases. Ann Med 1997; 29: 95-120. (Pubitemid 27226319)
11. Liggins J, Bluck LJ, Runswick S, Atkinson C, Coward WA, Bingham SA,. Daidzein and genistein content of fruits and nuts. J Nutr Biochem 2000; 11: 326-31.
12. Liggins J, Bluck LJ, Runswick S, Atkinson C, Coward WA, Bingham SA,. Daidzein and genistein contents of vegetables. Br J Nutr 2000; 84: 717-25.
13. Mazur WM, Wahala K, Rasku S, Salakka A, Hase T, Adlercreutz H,. Lignan and isoflavonoid concentrations in tea and coffee. Br J Nutr 1998; 79: 37-45. (Pubitemid 28058593)
14. Horn-Ross PL, John EM, Lee M, Stewart SL, Koo J, Sakoda LC, Shiau AC, Goldstein J, Davis P, Perez-Stable EJ,. Phytoestrogen consumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study. Am J Epidemiol 2001; 154: 434-41. (Pubitemid 32845481)
15. Linseisen J, Piller R, Hermann S, Chang-Claude J,. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2004; 110: 284-90. (Pubitemid 38580404)
16. Keinan-Boker L, van der Schouw YT, Grobbee DE, Peeters PH,. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 2004; 79: 282-8. (Pubitemid 41095982)
17. den T I, Keinan-Boker L, Veer PV, Arts CJ, Adlercreutz H, Thijssen JH, Peeters PH,. Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 223-8. (Pubitemid 34288533)
18. Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Adlercreutz H,. Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 2002; 155: 472-7. (Pubitemid 34174159)
19. Verheus M, van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters PH,. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007; 25: 648-55. (Pubitemid 350002919)
20. Ingram D, Sanders K, Kolybaba M, Lopez D,. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350: 990-4. (Pubitemid 27421108)
21. Zeleniuch-Jacquotte A, Adlercreutz H, Shore RE, Koenig KL, Kato I, Arslan AA, Toniolo P,. Circulating enterolactone and risk of breast cancer: a prospective study in New York. Br J Cancer 2004; 91: 99-105. (Pubitemid 39013052)
22. Buck K, Zaineddin AK, Vrieling A, Linseisen J, Chang-Claude J,. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr 2010; 92: 141-53.
23. Velentzis LS, Woodside JV, Cantwell MM, Leathem AJ, Keshtgar MR,. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur J Cancer 2008; 44: 1799-806.
24. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J,. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008; 123: 933-41. (Pubitemid 352032424)
25. Adlercreutz H, Wang GJ, Lapcik O, Hampl R, Wahala K, Makela T, Lusa K, Talme M, Mikola H,. Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 1998; 265: 208-15. (Pubitemid 29002063)
26. Wang GJ, Lapcik O, Hampl R, Uehara M, Al-Maharik N, Stumpf K, Mikola H, Wahala K, Adlercreutz H,. Time-resolved fluoroimmunoassay of plasma daidzein and genistein. Steroids 2000; 65: 339-48. (Pubitemid 30236340)
27. Remmele W, Stegner HE,. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987; 8: 138-40.
28. Remmele W, Schicketanz KH,. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993; 189: 862-6. (Pubitemid 23308006)
29. Royston P, Ambler G, Sauerbrei W,. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964-74. (Pubitemid 29525041)
30. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
31. Olsen A, Knudsen KE, Thomsen BL, Loft S, Stripp C, Overvad K, Moller S, Tjonneland A,. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2004; 13: 2084-9. (Pubitemid 40054302)
32. Dai Q, Franke AA, Jin F, Shu XO, Hebert JR, Custer LJ, Cheng J, Gao YT, Zheng W,. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 2002; 11: 815-21. (Pubitemid 35014883)
33. Kilkkinen A, Virtamo J, Vartiainen E, Sankila R, Virtanen MJ, Adlercreutz H, Pietinen P,. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study. Int J Cancer 2004; 108: 277-80. (Pubitemid 37541783)
34. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P,. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004; 90: 153-9. (Pubitemid 38174955)
35. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J,. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin d status. Cancer Epidemiol Biomarkers Prev 2008; 17: 1339-43.
36. Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H,. Determinants of serum enterolactone concentration. Am J Clin Nutr 2001; 73: 1094-100. (Pubitemid 32496950)
37. Adlercreutz H,. Lignans and human health. Crit Rev Clin Lab Sci 2007; 44: 483-525. (Pubitemid 47619399)
38. Piller R, Chang-Claude J, Linseisen J,. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur J Cancer Prev 2006; 15: 225-32. (Pubitemid 43791768)
39. Hulten K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G,. An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 2002; 41: 168-76. (Pubitemid 36056326)
40. Sonestedt E, Ivarsson MI, Harlid S, Ericson U, Gullberg B, Carlson J, Olsson H, Adlercreutz H, Wirfalt E,. The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. J Nutr 2009; 139: 993-1001.
41. Tham DM, Gardner CD, Haskell WL,. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998; 83: 2223-35. (Pubitemid 28503006)
42. Knight DC, Eden JA,. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996; 87: 897-904. (Pubitemid 26127148)
43. Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S,. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study. Breast Cancer Res 2008; 10: R32.
44. Touillaud MS, Thiebaut AC, Fournier A, Niravong M, Boutron-Ruault MC, Clavel-Chapelon F,. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 2007; 99: 475-86. (Pubitemid 47078736)
45. Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, Toniolo P,. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 1998; 7: 885-9. (Pubitemid 28471576)